

CURRENT AND FUTURE CHALLENGES IN THE LIFE SCIENCE INDUSTRY

AGENDA - Tuesday 2 April, 9:00-12:15

Venue: Danske Advokater - Vesterbrogade 32 - 1620 København V

Participation is free of charge.

If you participate in the event, you will receive a course certificate. This means that you can apply to the Danish Bar and Law Society for approval of 3 lessons for the purpose of your mandatory participation in the continuing education for lawyers and assistant attorneys.

Sign up for the event by sending an e-mail to dalila@dalila.dk

9:00 - 9:15	Welcome and introduction Søren Thor Jensen, Chairman of DALILA – Novo Nordisk A/S
9:15 - 9:45	First session: The Government's life science unit – status update and a peek into the future <ul style="list-style-type: none">• Status on the initiatives in the Government's growth plan, including<ul style="list-style-type: none">▪ Organization of clinical trials▪ Establishment of notified bodies in Denmark▪ Partnership for digital growth▪ SPC negotiations• Future challenges for the life science industry – from a government perspective Kasper Lindgaard , head of the Government's life science unit
9:45 - 10:00	Questions from the audience –Jacob Borum, DALILA board member - DLA Piper
10:00 - 10:30	Second session: A critical view of the political focus within life science <ul style="list-style-type: none">• The political focus within the life science sector – possibilities and threats• Do we need a growth plan for the life science sector?• A critical view on the government's work in the life science sector• Future challenges for the life science industry – from an industry perspective Henrik Vestergaard , vice CEO of the Danish Association of the Pharmaceutical Industry (Lif)
10:30 – 10:45	Questions from the audience –Jacob Borum, DALILA board member - DLA Piper
10:45 – 11:15	Pause/Networking
11:15 – 11:45	Third Session: Health and innovation in the EU – Challenges for the innovative pharmaceutical industry <ul style="list-style-type: none">• Innovation in Europe and IP as driver for innovation• IP incentives analysis• Facts and myths around pricing• Worrying trends – pharmacy compounding• Interplay between pharmaceutical pricing and competition• Need for dialogue with all stakeholders Kristine Peers , General Counsel, EFPIA - European Federation of Pharmaceutical Industries and Associations
11:45 – 12:00	Questions from the audience –Jacob Borum, DALILA board member - DLA Piper
12:00 -12:15	Concluding remarks Søren Thor Jensen, Chairman of DALILA – Novo Nordisk A/S